Cargando…
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute
This trial compared the efficacy and toxicity of standard first-line treatment with paclitaxel/carboplatin versus paclitaxel/carboplatin plus sorafenib in patients with advanced ovarian carcinoma. Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-12...
Autores principales: | Hainsworth, John D, Thompson, Dana S, Bismayer, John A, Gian, Victor G, Merritt, William M, Whorf, Robert C, Finney, Lindsey H, Dudley, B Stephens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430260/ https://www.ncbi.nlm.nih.gov/pubmed/25556916 http://dx.doi.org/10.1002/cam4.376 |
Ejemplares similares
-
Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel
por: Jilaveanu, Lucia B., et al.
Publicado: (2013) -
Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)
por: Battiwalla, Minoo, et al.
Publicado: (2020) -
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023) -
Regular cannon wave
por: Ranjith, Mangalachulli Pottammal, et al.
Publicado: (2016) -
On the Wind of a Cannon-Ball
por: Bagnold,
Publicado: (1817)